Earned Media GEO Turns AI into Clinical Discovery Tool — Impact on HUTCHMED (China)
- Over 800 million people use AI for answers each week.
- 94% of links cited by AI systems come from non-paid media.
- Credible earned-media placements are crucial for biopharma firms like HUTCHMED (China).
AI-driven media becomes clinical discovery tool for drugmakers
Earned coverage as the backbone of LLM-driven clinical discovery
HCM, a PR agency focused on impact-driven brands, is expanding Generative Engine Optimization (GEO) services that position earned media as the primary source LLMs cite when answering healthcare queries. The firm says more than 800 million people use AI for answers weekly and that 94% of links cited by those AI systems come from non-paid media, a dynamic that makes credible media placements crucial for biopharmaceutical companies such as HUTCHMED (China). The development shifts communications strategy from chasing algorithms to building authoritative narratives that large language models will surface to patients, clinicians and partners.
HCM’s GEO approach fuses traditional media relations with LLM-ready educational explainers and multi-channel syndication, aiming to create the trust signals that drive AI discovery. The agency combines data-driven story ideation, prompt engineering and targeted syndication so that high-credibility coverage is amplified across owned channels, newsletters and social platforms, increasing the chance that models such as ChatGPT, Claude and Gemini reference a company’s materials when responding to queries on disease, trial results or drug safety. CEO Hannah Cranston frames the work as amplifying, not replacing, conventional PR: without clear, widely distributed narratives, she says, AI has little reliable content to reference.
For biopharma firms, the implication is significant: clinical trial results, safety updates and educational materials must be crafted both for human reporters and for LLM ingestion to ensure accurate downstream discovery. GEO is presented as infrastructure that sustains visibility over time, helping companies control the framing of complex scientific outcomes and reducing the risk that AI-driven answers surface incomplete or misleading sources when patients and healthcare professionals seek information.
Early client outcomes illustrate practical gains
HCM cites client cases where educational content and strategic earned placements drive measurable traffic and AI visibility: one client sees a 400% website traffic increase after positioning educational material in response to a major study; a social fitness platform achieves prominent placement in AI-generated recommendations following syndicated coverage in outlets including Business Insider; and a wellness brand secures durable LLM-driven discovery through timely newsjacking and tabloid placement.
GEO’s proprietary methodology compounds authority signals by pairing earned credibility with explainers optimized for LLMs and amplifying them across channels. For companies in the pharmaceutical and healthcare sectors, HCM positions the approach as a strategic investment to protect reputation, improve discovery of clinical information and ensure authoritative sources surface in AI-powered patient and clinician queries.
Related Cashu News

CRISPR Therapeutics AG Achieves Financial Progress Amid Advancements in Gene-Editing Portfolio
CRISPR Therapeutics AG (Ticker: UNDEFINED) showcases a pivotal moment in its financial journey with the release of its results for the first quarter of 2026. Highlighting a revenue of $1.46 million, t…

MetaVia to Present Innovative Cardiometabolic Research at 2026 ADA Scientific Sessions
MetaVia is set to showcase its innovative research in cardiometabolic diseases at the upcoming American Diabetes Association (ADA) Scientific Sessions in 2026, following the acceptance of three late-b…

Ionis Pharmaceuticals Advances TRYNGOLZA for Hypertriglyceridemia and Diranersen for Alzheimer's Disease
Ionis Pharmaceuticals has made headlines in the biotechnology sector with the promising potential of its drug TRYNGOLZA, which is designed to treat severe hypertriglyceridemia. During a recent healthc…

ImmunityBio Partners with BCG Laboratory to Enhance Bladder Cancer Treatment Supply and Options
ImmunityBio has secured a critical partnership with Japan's BCG Laboratory to enhance the supply of Bacillus Calmette-Guérin (BCG) in the United States, addressing an urgent need in the treatment of b…